Catalyst Wire Dossier Catalyst Wire Dossier

PNEUMOVAX23

pneumococcal polysaccharide vaccine · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for PNEUMOVAX23, covering 2020-11-25 to 2021-01-15. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY) [Phase 3]

See pricing